Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Kommende kliniske forsøg
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and...Ikke rekrutterer endnuMotor færdigheder | Sund og rask | Executive funktion
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCIkke rekrutterer endnuAnal planocellulært karcinom
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaIkke rekrutterer endnuRheumatoid arthritis | Degenerativ ledsygdom i knæetItalien
-
University of Wisconsin, MadisonAlkermes, Inc.Ikke rekrutterer endnu
-
Virginia Commonwealth UniversityIkke rekrutterer endnuCerebralt ødem | StrålingsnekroseForenede Stater
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at...Ikke rekrutterer endnuKetamin | fMRI | Depression - svær depressiv lidelse | rTMS | Behandlingsresistent depression (TRD)Forenede Stater
-
Weill Medical College of Cornell UniversityBD2 LLCIkke rekrutterer endnufMRI | Bipolar lidelse (BD) | rTMS | Bipolar 1 depressionForenede Stater
-
Xentria, Inc.Ikke rekrutterer endnu
-
Yale UniversityNational Institute of Mental Health (NIMH)Ikke rekrutterer endnu
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRekrutteringFæokromocytom | Fæokromocytom/Paragangliom | Fæokromocytom, metastatisk | Malignt fæokromocytom | Pheochromocytoma og paraganglioma (PPGL)Det Forenede Kongerige
-
Carl Zeiss Meditec-Dublin CoCeRekrutteringEpiretinal membran | Nethindesygdom | Tør aldersrelateret makuladegeneration | Vitreoretinal abnormitet | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium...Forenede Stater
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityRekruttering
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China
